Micro RNA 33 as a potential therapeutic target in chronic hepatitis c
| Project/Area Number |
25670357
|
|---|
| Research Category |
Grant-in-Aid for Challenging Exploratory Research
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
General internal medicine(including psychosomatic medicine)
|
|---|
| Research Institution | Yokohama City University |
|---|
Principal Investigator |
TOMENO Wataru 横浜市立大学, 附属病院, 指導診療医 (00644957)
|
|---|
| Research Collaborator |
SAITO Satoru
|
|---|
| Project Period (FY) |
2013-04-01 – 2015-03-31
|
| Project Status |
Completed (Fiscal Year 2014)
|
| Budget Amount *help |
¥3,770,000 (Direct Cost: ¥2,900,000、Indirect Cost: ¥870,000)
Fiscal Year 2014: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2013: ¥2,210,000 (Direct Cost: ¥1,700,000、Indirect Cost: ¥510,000)
|
|---|
| Keywords | C型慢性肝炎 / マイクロRNA33 / 消化器内科 / 基礎医学 / C型肝炎治療 |
|---|
| Outline of Final Research Achievements |
Micro RNA 33b (miR-33b) contributes to the regulation of cholesterol homeostasis in cooperation with sterol regulatory element-binding protein (SREBP).We transfected a miR-33b inhibitor into hepatitis c virus (HCV) replicon to examine whether the nucleic acid could inhibit HCV replication. We expected that the expression of miR-33b was upregulated in order to make the lipid-rich environment that HCV was easy to replicate. However, the significant difference was not detected in expression of miR-33b not only in HCV replicon cells but also in the liver biopsy specimens of the chronic hepatitis c patients. Because both the expression of HCV protein and the replication of HCV RNA have not changed significantly after transfection of the miR-33b inhibitor, we were not able to find the usefulness of the agent as the new anti-viral drug.
|
Report
(3 results)
Research Products
(2 results)
